Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dRAvite-LTE: Long-term Extension Study of Afimkibart in Rheumatoid Arthritis
NCT07620392Phase 2Recruiting
- Sponsor
- Roche
- Start
- Jun 2026
- Primary completion
- Jul 2033
- Countries
- 3
01
Overview
Phase 2, open-label trial of afimkibart in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Adverse Events up to 6 years. Started Jun 2026; status: recruiting.
02
Drugs
afimkibart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07620392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620392.